for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Recro Pharma Inc

REPH.OQ

Latest Trade

11.84USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

5.55

 - 

12.66

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.84
Open
--
Volume
--
3M AVG Volume
4.09
Today's High
--
Today's Low
--
52 Week High
12.66
52 Week Low
5.55
Shares Out (MIL)
22.43
Market Cap (MIL)
265.54
Forward P/E
-19.57
Dividend (Yield %)
--

Latest Developments

More

Recro Pharma Q2 Loss Per Share $0.13

Recro Pharma Reports Q1 Loss Per Share Of $0.09

Recro Pharma Inc says Will Incur About $4 Mln Of Costs In Connection With Workforce Reduction

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Recro Pharma Inc

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Industry

Biotechnology & Drugs

Contact Info

490 Lapp Rd

+1.484.3952400

https://recropharma.com/

Executive Leadership

Wayne B. Weisman

Independent Chairman of the Board

Geraldine A. Henwood

President, Chief Executive Officer, Director

Ryan D. Lake

Chief Financial Officer

Jyrki Mattila

Executive Vice President - Business Development

Randall Mack

Senior Vice President - Development, Secretary

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-2.820

2017

-1.990

2018

-3.900

2019(E)

-0.605
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.87
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-41.81
Return on Equity (TTM)
-34.69

Latest News

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

BRIEF-Recro Pharma Receives Complete Response Letter From FDA

* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

BRIEF-Recro Pharma Reports Q1 Loss Per Share Of $0.65

* Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S

BRIEF-Recro Pharma Announces Receipt Of Issue Notifications For Three New Patents For Iv Meloxicam

* RECRO PHARMA ANNOUNCES RECEIPT OF ISSUE NOTIFICATIONS FOR THREE NEW PATENTS FOR IV MELOXICAM Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma Inc Reports Year End 2017 Financial Results

* RECRO PHARMA INC - FOR 2018, COMPANY EXPECTS REVENUE GENERATED FROM ITS CDMO DIVISION TO BE APPROXIMATELY $70 MILLION

BRIEF-Recro Pharma Estimates Cash And Cash Equivalents About $64 Mln As Of Dec 31

* RECRO PHARMA - ESTIMATES THAT AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $64.0 MILLION Source text for Eikon: (http://bit.ly/2nOPGN7) Further company coverage:

BRIEF-Recro Pharma - ‍Ryan Lake Promoted To CFO

* RECRO PHARMA INC - RYAN D. LAKE HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co

* RECRO PHARMA INC - ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP

BRIEF-Recro Pharma reports Q3 revenue $17.1 million

* Recro Pharma Inc - Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million

BRIEF-RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG

* RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg

* Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Recro Pharma quarterly ‍loss per share $0.48

* Qtrly loss per share $0.48; Co is raising its guidance for 2017 revenue from a range of $55-$60 million to $60-$63 million Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma submits new drug application for IV Meloxicam 30mg

* Recro Pharma submits new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma acquires Novel Neuromuscular blocking agents

* Says under terms of agreement, Recro Pharma will pay Cornell a six figure initial up-front fee

BRIEF-Recro Pharma files for mixed shelf of up to $100 mln - SEC Filing

* Recro pharma files for mixed shelf of up to $100 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma presents Phase III bunionectomy clinical data for IV meloxicam

* Recro Pharma presents Phase III bunionectomy clinical data for IV meloxicam at the American Pain Society 36th annual scientific meeting

BRIEF-Recro Pharma reports Q1 loss per share of $0.42

* Q1 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

BRIEF-Recro Pharma announces successful top-line results from phase III safety study of iv meloxicam

* Recro pharma announces successful top-line results from phase iii safety study of iv meloxicam

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up